Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: LRY044
MIFTS: 60

Larynx Cancer

Categories: Rare diseases, Cancer diseases, Respiratory diseases, Oral diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Larynx Cancer

About this section

MalaCards integrated aliases for Larynx Cancer:

Name: Larynx Cancer 12 15
Laryngeal Carcinoma 12 76 53 29 55 15
Laryngeal Cancer 53 37 55
Laryngeal Benign Neoplasm 12 15
Carcinoma of Larynx 12 73
Laryngeal Neoplasm 76 73
Malignant Neoplasm of Larynx 73
Laryngeal Neoplasms 44
Neoplasm of Larynx 12
Cancer, Laryngeal 40
Cancer of Larynx 12
Laryngeal Tumor 12
Larynx Neoplasm 12

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Respiratory diseases Oral diseases
See all MalaCards categories (disease lists)
ICD10: 33


Sources

Summaries for Larynx Cancer

About this section
Disease Ontology : 12 A larynx cancer that has material basis in epithelial cells.

MalaCards based summary : Larynx Cancer, also known as laryngeal carcinoma, is related to squamous cell carcinoma and supraglottic laryngeal cancer. An important gene associated with Larynx Cancer is MIR21 (MicroRNA 21
To investigate whether specific miRNAs and their target genes participate in the molecular pathogenesis of laryngeal carcinoma, oligonucleotide microarrays were used to assess the differential expression profiles of microRNAs and mRNAs in laryngeal carcinoma tissues compared with normal tissues. The oncogenic miRNA, microRNA-21 (miR-21), was found to be upregulated in laryngeal carcinoma tissues. Knockdown of miR-21 by specific antisense oligonucleotides inhibited the proliferation potential of HEp-2 cells, whereas overexpression of miR-21 elevated growth activity of the cells, as detected by the colony formation assay. The cell number reduction caused by miR-21 inhibition was due to the loss of control of the G1-S phase transition, instead of a noticeable increase in apoptosis. Subsequently, a new target gene of miR-21, BTG2, was found to be downregulated in laryngeal carcinoma tissues. BTG2 is known to act as a pan-cell cycle regulator and tumor suppressor. These findings indicate that aberrant expression of miR-21 may contribute to the malignant phenotype of laryngeal carcinoma by maintaining a low level of BTG2. The identification of the oncogenic miR-21 and its target gene, BTG2, in laryngeal carcinoma is potentially valuable for cancer diagnosis and therapy.), and among its related pathways/superpathways are Endometrial cancer and Drug metabolism - cytochrome P450. The drugs Bupropion and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include lung, lymph node and skin, and related phenotypes are Reduced mammosphere formation and digestive/alimentary

Wikipedia : 76 Laryngeal cancer, also known as cancer of the larynx or laryngeal carcinoma, are mostly squamous cell... more...

Sources

Related Diseases for Larynx Cancer

About this section

Diseases in the Larynx Cancer family:

Larynx Carcinoma in Situ

Diseases related to Larynx Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 139)
# Related Disease Score Top Affiliating Genes
1 squamous cell carcinoma 29.3 CCND1 CD44 CDKN2A EGFR GSTP1 NME1
2 supraglottic laryngeal cancer 11.3
3 laryngeal neuroendocrine tumor 11.0
4 laryngeal mucoepidermoid carcinoma 11.0
5 laryngeal adenoid cystic carcinoma 11.0
6 laryngeal small cell carcinoma 11.0
7 hearing loss, noise-induced 11.0 GSTM1 GSTT1
8 brain stem astrocytic neoplasm 10.9 CDKN2A TP53
9 larynx sarcoma 10.9
10 drug-induced hepatitis 10.9 GSTM1 GSTT1 NAT2
11 breast papillomatosis 10.9 CCND1 CDKN2A
12 diffuse gastric cancer 10.8 GSTM1 GSTP1 GSTT1
13 sister chromatid exchange, frequency of 10.8 GSTM1 GSTT1
14 asbestosis 10.8 GSTM1 GSTP1 GSTT1
15 xeroderma pigmentosum, complementation group d 10.8 GSTM1 GSTP1 GSTT1
16 anal canal carcinoma 10.8 CDKN2A NME1
17 gastric adenosquamous carcinoma 10.8 CD44 CDKN2A TP53
18 endometrial clear cell adenocarcinoma 10.7 CTSD TP53
19 oral submucous fibrosis 10.7 GSTM1 GSTT1 MMP2
20 juvenile pilocytic astrocytoma 10.7 CD44 CDKN2A TP53
21 vulvar intraepithelial neoplasia 10.6 MMP2 TP53
22 keratinizing squamous cell carcinoma 10.6 CDKN2A TP53
23 actinic keratosis 10.6 CDKN2A MMP2 TP53
24 acute lymphocytic leukemia 10.6 CDKN2A GSTM1 GSTT1 TP53
25 gastrointestinal system benign neoplasm 10.6 CCND1 CDKN2A TP53
26 brain ependymoma 10.6 EGFR TP53
27 retinal cancer 10.6 CCND1 CDKN2A TP53
28 sensory system cancer 10.6 CCND1 CDKN2A TP53
29 bowenoid papulosis 10.5 CCND1 CDKN2A TERT
30 malignant peritoneal mesothelioma 10.5 CDKN2A EGFR
31 megaesophagus 10.5 CDKN2A FHIT TP53
32 cervix uteri carcinoma in situ 10.5 CDKN2A FHIT TP53
33 skin carcinoma in situ 10.5 CCND1 CDKN2A
34 suppressor of tumorigenicity 3 10.5 CDKN2A FHIT TP53
35 spitz nevus 10.5 CDKN2A TP53
36 ocular cancer 10.5 CCND1 CDKN2A TP53
37 ovarian cancer 1 10.5 MMP2 NME1 TP53
38 cell type benign neoplasm 10.5 CCND1 CDKN2A TP53
39 barrett's adenocarcinoma 10.5 CDKN2A FHIT TP53
40 bladder papillary transitional cell neoplasm 10.5 TERT TP53
41 cervix carcinoma 10.5 CDKN2A FHIT TP53
42 nervous system cancer 10.5 CCND1 CDKN2A TP53
43 male reproductive organ cancer 10.5 CCND1 GSTP1 TP53
44 urinary tract papillary transitional cell benign neoplasm 10.5 TERT TP53
45 oral leukoplakia 10.5 CCND1 CDKN2A GSTM1 TP53
46 basal cell carcinoma 10.4 GSTM1 GSTM3 GSTT1 TP53
47 melanoma, cutaneous malignant 1 10.4 CDKN2A TERT TP53
48 villous adenocarcinoma 10.4 EGFR MMP2
49 oropharynx cancer 10.4 CDKN2A EGFR TP53
50 basaloid squamous cell carcinoma 10.4 CDKN2A EGFR TP53

Comorbidity relations with Larynx Cancer via Phenotypic Disease Network (PDN):


Bronchitis Deficiency Anemia
Pharynx Cancer Protein-Energy Malnutrition
Respiratory Failure Supraglottis Cancer
Swallowing Disorders

Graphical network of the top 20 diseases related to Larynx Cancer:



Diseases related to Larynx Cancer
Sources

Symptoms & Phenotypes for Larynx Cancer

About this section

GenomeRNAi Phenotypes related to Larynx Cancer according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.17 CCND1 CD44 EGFR GSTM1 GSTM3 MMP2

MGI Mouse Phenotypes related to Larynx Cancer:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.91 FHIT TERT CCND1 TP53 CD44 CDKN2A
2 integument MP:0010771 9.81 ENG FHIT NME1 CCND1 TP53 CD44
3 neoplasm MP:0002006 9.61 FHIT MMP2 NME1 TERT CCND1 TP53
4 respiratory system MP:0005388 9.23 ENG MMP2 TERT CCND1 TP53 CD44
Sources

Drugs & Therapeutics for Larynx Cancer

About this section

Drugs for Larynx Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 312)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bupropion Approved Phase 4,Phase 2 34841-39-9, 34911-55-2 444
2
Dopamine Approved Phase 4,Phase 2 51-61-6, 62-31-7 681
3
Nicotine Approved Phase 4,Not Applicable 54-11-5 942 89594
4 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 2,Phase 3
5 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
6 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Not Applicable
7 Autonomic Agents Phase 4,Phase 3,Phase 2,Not Applicable
8 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
9 Antidepressive Agents Phase 4,Phase 3,Phase 2,Not Applicable
10 Antidepressive Agents, Second-Generation Phase 4,Phase 2
11 Cytochrome P-450 CYP2D6 Inhibitors Phase 4,Phase 2
12 Dopamine Agents Phase 4,Phase 2
13 Dopamine Uptake Inhibitors Phase 4,Phase 2
14 Neurotransmitter Uptake Inhibitors Phase 4,Phase 2
15 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Not Applicable
16 Central Nervous System Stimulants Phase 4,Phase 3,Not Applicable
17 Cholinergic Agents Phase 4,Phase 2,Phase 3,Not Applicable
18 Nicotinic Agonists Phase 4,Not Applicable
19
Tegafur Approved, Investigational Phase 3 17902-23-7 5386
20
Cisplatin Approved Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 15663-27-1 84093 441203 2767
21
Epinephrine Approved, Vet_approved Phase 3,Phase 2 51-43-4 5816
22
Epirubicin Approved Phase 3,Phase 2,Phase 1 56420-45-2 41867
23
Racepinephrine Approved Phase 3,Phase 2 329-65-7 838
24
Fluorouracil Approved Phase 3,Phase 2,Phase 1 51-21-8 3385
25
Docetaxel Approved, Investigational Phase 3,Phase 2,Phase 1 114977-28-5 148124
26
Ethanol Approved Phase 3 64-17-5 702
27
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
28
Hydroxyurea Approved Phase 3,Phase 2,Phase 1 127-07-1 3657
29
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3,Not Applicable 437-38-7 3345
30
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 33069-62-4 36314
31
Cetuximab Approved Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 205923-56-4 56842117 2333
32
Cefazolin Approved Phase 3 25953-19-9 656510 33255
33
Pilocarpine Approved, Investigational Phase 2, Phase 3 54-71-7, 92-13-7 5910
34
Doxepin Approved, Investigational Phase 3,Not Applicable 1668-19-5 667477 667468
35
Histamine Approved, Investigational Phase 3,Not Applicable 75614-87-8, 51-45-6 774
36
Fluconazole Approved, Investigational Phase 2, Phase 3 86386-73-4 3365
37
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3,Phase 1 22916-47-8 4189
38
Cevimeline Approved Phase 3 107233-08-9 83898 25137844
39
Megestrol acetate Approved, Investigational, Vet_approved Phase 3 595-33-5 11683
40
Bleomycin Approved, Investigational Phase 3 11056-06-7 5360373
41
Levoleucovorin Approved, Investigational Phase 3,Phase 2 68538-85-2
42
Methotrexate Approved Phase 3,Phase 2 1959-05-2, 59-05-2 126941
43
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
44
Isotretinoin Approved Phase 3,Phase 2 4759-48-2 5538 5282379
45
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1 135968-09-1
46
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
47
Niacin Approved, Investigational, Nutraceutical Phase 3,Phase 2,Phase 1 59-67-6 938
48
Nicotinamide Approved, Investigational, Nutraceutical Phase 3,Phase 2,Phase 1 98-92-0 936
49
leucovorin Approved, Nutraceutical Phase 3,Phase 2,Phase 1 58-05-9 143 6006
50
Tocopherol Approved, Investigational, Nutraceutical Phase 3 1406-66-2 14986

Interventional clinical trials:

(show top 50) (show all 410)
# Name Status NCT ID Phase Drugs
1 Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking Completed NCT00666978 Phase 4 bupropion hydrochloride
2 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
3 Effect of Magnesium Sulphate Infusion on Lung Mechanics and Oxygenation in COPD Patients Undergoing Total Laryngeal Recruiting NCT03461328 Phase 4 Magnesium Sulphate
4 the Comparison of Voice Quality in Early Laryngeal Cancer Between Surgery and Radiotherapy Unknown status NCT00497588 Phase 3
5 Evaluation of 3DCRT Versus IGRT and Analysis of Early Response in Head and Neck Cancer. Unknown status NCT01124409 Phase 3
6 PET/CT Scan-Guided Watchful Waiting or Neck Dissection of Locally Advanced Lymph Node Metastases in Treating Patients Undergoing Chemotherapy and Radiation Therapy for Primary Head And Neck Cancer Unknown status NCT00720070 Phase 3
7 S-1 or Tegafur-Uracil in Treating Patients With Previously Treated Stage III or Stage IV Head and Neck Cancer Unknown status NCT00336947 Phase 3 tegafur-gimeracil-oteracil potassium;tegafur-uracil
8 Cisplatin Plus Epinephrine in Treating Patients With Recurrent or Refractory Head and Neck Cancer Unknown status NCT00002659 Phase 3 cisplatin-e therapeutic implant
9 Radiation Therapy With or Without Chemotherapy in Treating Patients With Advanced Cancer of the Larynx Completed NCT00002496 Phase 3 chemotherapy;cisplatin;fluorouracil
10 Randomized Trial of ARCON in Larynx Cancer Completed NCT00147732 Phase 3
11 Induction CT by Cisplatin, 5FU With or Without Docetaxel in Patients With T3 and T4 Larynx and Hypopharynx Carcinoma Completed NCT00169182 Phase 3 DOCETAXEL
12 Combination Chemotherapy Plus Radiation Therapy To Preserve the Larynx in Patients With Cancer of the Hypopharynx or Larynx Completed NCT00002839 Phase 3 cisplatin;fluorouracil
13 Comparison of 2 Cefazolin Prophylactic Protocol in Laryngectomy Patients Completed NCT00467948 Phase 3 cefazolin
14 Randomized Trial to Assess the Impact of a Screening Program on Upper Aerodigestive Tract Cancer Mortality in a High Risk Population Completed NCT00359645 Phase 3
15 Very Intense Radiotherapy-Chemotherapy Regimen in Advanced HNSCC Completed NCT00162708 Phase 2, Phase 3 CDDP, 5 Fu
16 Accelerated Radiotherapy and Concomitant Chemo-radiotherapy in HNSCC Completed NCT00158652 Phase 3 5FU, Paraplatin
17 Docetaxel Based Chemotherapy Plus or Minus Induction Chemotherapy to Decrease Events in Head and Neck Cancer (DeCIDE) Completed NCT00117572 Phase 3 docetaxel;cisplatin;hydroxyurea;fluorouracil
18 Acupuncture-Like Transcutaneous Electrical Nerve Stimulation (ALTENS) or Pilocarpine in Treating Early Dry Mouth in Patients Undergoing Radiation Therapy for Head and Neck Cancer Completed NCT00656513 Phase 2, Phase 3 Pilocarpine
19 Sargramostim in Decreasing Mucositis in Patients Receiving Radiation Therapy for Head and Neck Cancer Completed NCT00008398 Phase 3
20 Radiation Therapy in Treating Patients With Stage II Cancer of the Vocal Cord Completed NCT00002727 Phase 3
21 Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy Completed NCT01156142 Phase 3 doxepin hydrochloride
22 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
23 Acupuncture or Standard Therapy in Treating Pain and Dysfunction in Patients Who Have Undergone Neck Surgery for Head and Neck Cancer Completed NCT00090337 Phase 3
24 Fluconazole in Preventing Mucositis in Patients Undergoing Radiation Therapy for Head and Neck Cancer Completed NCT00002533 Phase 2, Phase 3 fluconazole
25 Study of Nutrition Regimens in Treating Patients With Cancer of the Upper Aerodigestive Tract Completed NCT00765440 Phase 3
26 Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck Cancer Completed NCT00017511 Phase 3 cevimeline hydrochloride
27 Radiation Therapy and Cisplatin or Panitumumab in Treating Patients With Locally Advanced Stage III or Stage IV Head and Neck Cancer Completed NCT00820248 Phase 3 cisplatin
28 Megestrol to Limit Weight Loss and Improve Quality of Life in Treating Patients With Head and Neck Cancer Completed NCT00006799 Phase 3 megestrol acetate
29 Radiation Therapy With or Without Chemotherapy in Treating Patients With Advanced Head and Neck Cancer Completed NCT00002476 Phase 3 fluorouracil;leucovorin calcium;methotrexate;vincristine sulfate
30 Radiation Therapy and Chemotherapy in Treating Patients With Head and Neck Cancer Completed NCT00002507 Phase 3 mitomycin C;porfiromycin
31 Oral Mucositis in Patients Receiving Radiation Therapy for Cancer of the Mouth, Pharynx, or Larynx Completed NCT00004234 Phase 3
32 Radiation Therapy in Treating Patients With Head and Neck Cancer Completed NCT00021125 Phase 3
33 Radiation Therapy With or Without Epoetin Alfa in Treating Anemic Patients With Head and Neck Cancer Completed NCT00004917 Phase 3 cisplatin
34 Combination Chemotherapy in Treating Patients With Advanced Head and Neck Cancer Completed NCT00002888 Phase 3 cisplatin;fluorouracil;paclitaxel
35 Cisplatin With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic or Recurrent Head and Neck Cancer Completed NCT00003809 Phase 3 cisplatin
36 Radiation Therapy With or Without Chemotherapy in Treating Patients With Head and Neck Cancer That Has Been Removed During Surgery Completed NCT00002670 Phase 3 chemotherapy;cisplatin
37 Combination Chemotherapy and Radiation in Treating Patients With Stage III or IV Head and Neck Cancer (Paradigm Trial) Completed NCT00095875 Phase 3 carboplatin;cisplatin;docetaxel;fluorouracil
38 Radiation Therapy Cisplatin With or Without Fluorouracil Patients With Stage III or Stage IV Head and Neck Cancer Completed NCT00608205 Phase 3 cisplatin;fluorouracil
39 Methotrexate Compared With Paclitaxel in Treating Patients With Advanced Head and Neck Cancer Completed NCT00003592 Phase 3 methotrexate;paclitaxel
40 Fractionated Radiation Therapy in Treating Advanced Squamous Cell Carcinoma of the Head and Neck Completed NCT00771641 Phase 3
41 Isotretinoin, Interferon Alfa, and Vitamin E in Treating Patients With Stage III or Stage IV Head and Neck Cancer Completed NCT00054561 Phase 3 isotretinoin
42 Radiation Therapy Plus Porfiromycin in Treating Patients With Stage III or Stage IV Head and Neck Cancer Completed NCT00003328 Phase 3 porfiromycin
43 Radiation Therapy With or Without Cisplatin in Treating Patients With Advanced Head and Neck Cancer Completed NCT00002654 Phase 3 chemotherapy;cisplatin
44 High-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With Head and Neck Cancer Completed NCT00002555 Phase 3 cisplatin
45 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer Completed NCT00003888 Phase 3 cisplatin;docetaxel;fluorouracil
46 Biafine Cream to Reduce Side Effects of Radiation Therapy in Patients Receiving Treatment for Advanced Head and Neck Cancer Completed NCT00006481 Phase 3 Biafine cream
47 Surgery and Radiation Therapy Compared With Chemotherapy and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer That Can Be Removed During Surgery Completed NCT00003576 Phase 3 cisplatin;fluorouracil
48 Definitive Chemo-Radiotherapy for Regionally Advanced Head and Neck Cancer With or Without Up-front Neck Dissection Recruiting NCT02918955 Phase 3 Chemotherapy (Cisplatin)
49 Acupuncture in Treating Dry Mouth Caused By Radiation Therapy in Patients With Head and Neck Cancer Active, not recruiting NCT01141231 Phase 3
50 Radiation Therapy With Cisplatin, Docetaxel, or Cetuximab After Surgery in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer Active, not recruiting NCT01810913 Phase 2, Phase 3 cisplatin;docetaxel

Search NIH Clinical Center for Larynx Cancer

Cochrane evidence based reviews: laryngeal neoplasms

Sources

Genetic Tests for Larynx Cancer

About this section

Genetic tests related to Larynx Cancer:

# Genetic test Affiliating Genes
1 Laryngeal Carcinoma 29
Sources

Anatomical Context for Larynx Cancer

About this section

MalaCards organs/tissues related to Larynx Cancer:

41
Lung, Lymph Node, Skin, Liver, Brain, Endothelial, Testes
Sources

Publications for Larynx Cancer

About this section

Articles related to Larynx Cancer:

(show top 50) (show all 832)
# Title Authors Year
1
Quality of life in patients with larynx cancer in Latin America: Comparison between laryngectomy and organ preservation protocols. ( 29554402 )
2018
2
Epidemiological features of cancers of the oral cavity, oropharynx, hypopharynx and larynx cancer in RAcunion Island. ( 29673737 )
2018
3
Three-dimensional imaging assessment of anatomic invasion and volumetric considerations for chemo/radiotherapy-based laryngeal preservation in T3 larynx cancer. ( 29598944 )
2018
4
Laryngeal Tuberculosis Mimicking Laryngeal Carcinoma on <sup>18</sup>F-FDG PET/CT Imaging. ( 29889030 )
2018
5
Impact of HPV Status on the Prognostic Potential of the AJCC Staging System for Larynx Cancer. ( 29611770 )
2018
6
Downregulation of miRNA-26b inhibits cancer proliferation of laryngeal carcinoma through autophagy by targeting ULK2 and inactivation of the PTEN/AKT pathway. ( 28713931 )
2017
7
Salvage Surgery after Radiation Failure in T1/T2 Larynx Cancer: Outcomes following Total versus Conservation Surgery. ( 29292665 )
2017
8
MiR-503 enhances the radiosensitivity of laryngeal carcinoma cells via the inhibition of WEE1. ( 29019284 )
2017
9
Histone Deacetylase Inhibitor SAHA as Potential Targeted Therapy Agent for Larynx Cancer Cells. ( 28123594 )
2017
10
Characterizing an Ultra-High-Risk Subset of Patients With Hypopharynx and Larynx Cancer: The Power of Lymph Node Burden. ( 29192300 )
2017
11
Development and external validation of a risk-prediction model to predict 5-year overall survival in advanced larynx cancer. ( 29114897 )
2017
12
<i>Saccharomyces cerevisiae</i> Laryngitis and Oral Lesions in a Patient with Laryngeal Carcinoma. ( 29318065 )
2017
13
Galangin suppresses human laryngeal carcinoma via modulation of caspase-3 and AKT signaling pathways. ( 28677816 )
2017
14
The expression and function of epithelial membrane protein 1 in laryngeal carcinoma. ( 27909719 )
2017
15
Bcl-2 overexpression contributes to laryngeal carcinoma cell survival by forming a complex with Hsp90I^. ( 27959448 )
2017
16
MicroRNA-195 inhibits growth and invasion of laryngeal carcinoma cells by directly targeting DCUN1D1. ( 28791411 )
2017
17
Neck Management with Total Laryngectomy and Adjuvant Radiotherapy in Locally Advanced Larynx Cancer. ( 28848123 )
2017
18
Incidence rate for larynx cancer in Japanese in Japan and in the United States from the Cancer Incidence in Five Continents. ( 28407079 )
2017
19
Patterns of fractionation for patients with T2N0M0 glottic larynx cancer undergoing definitive radiotherapy in the United States. ( 28797446 )
2017
20
Effect of rural and urban geography on larynx cancer incidence and survival. ( 29238975 )
2017
21
The Prognostic Value of Epithelial Membrane Protein 1 (EMP-1) in Patients with Laryngeal Carcinoma. ( 28779068 )
2017
22
[Forkhead domain inhibitor-6 (FDI-6) increases apoptosis and inhibits invasion and migration of laryngeal carcinoma cells by down-regulating nuclear FoxM1]. ( 28502298 )
2017
23
An update on larynx cancer. ( 27898173 )
2017
24
Nuclear survivin expression correlates with endoglin-assessed microvascularisation in laryngeal carcinoma. ( 28446541 )
2017
25
Treatment, short-term outcomes, and costs associated with larynx cancer care in commercially insured patients. ( 28685830 )
2017
26
Altered Expression of miRNAs Is Related to Larynx Cancer TNM Stage and Patients' Smoking Status. ( 28430523 )
2017
27
SBRT for early-stage glottic larynx cancer-Initial clinical outcomes from a phase I clinical trial. ( 28253270 )
2017
28
MicroRNA-133a suppresses the proliferation, migration, and invasion of laryngeal carcinoma cells by targeting CD47. ( 27730543 )
2016
29
Classification of TP53 mutations and HPV predict survival in advanced larynx cancer. ( 27345657 )
2016
30
Downregulation of miR-34a contributes to the proliferation and migration of laryngeal carcinoma cells by targeting cyclin D1. ( 27220728 )
2016
31
A comparison of overall survival for patients with T4 larynx cancer treated with surgical versus organ-preservation approaches: A National Cancer Data Base analysis. ( 27727461 )
2016
32
Functional state of the Hsp27 chaperone as a molecular marker of an unfavorable course of larynx cancer. ( 27540972 )
2016
33
Lymph Node Density in Node-Positive Laryngeal Carcinoma: Analysis of Prognostic Value for Survival. ( 27221573 )
2016
34
Long-term quality of life after transoral laser microsurgery for laryngeal carcinoma. ( 27709626 )
2016
35
Relation between Endothelial Nitric Oxide Synthase Genotypes and Oxidative Stress Markers in Larynx Cancer. ( 26682008 )
2016
36
miR-148a and miR-375 may serve as predictive biomarkers for early diagnosis of laryngeal carcinoma. ( 27446362 )
2016
37
Identification of key target genes and pathways in laryngeal carcinoma. ( 27446427 )
2016
38
Expression of Th1- Th2- and Th17-associated cytokines in laryngeal carcinoma. ( 27588143 )
2016
39
The pre-treatment neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and red cell distribution width predict prognosis in patients with laryngeal carcinoma. ( 27520567 )
2016
40
Aspergilloma Mimicking Metastasis in a Case with Laryngeal Carcinoma. ( 26980939 )
2016
41
Epidemiology of laryngeal carcinoma in Germany, 1998-2011. ( 26879991 )
2016
42
Comparison of CT and MRI in Diagnosis of Laryngeal Carcinoma with Anterior Vocal Commissure Involvement. ( 27480073 )
2016
43
Adenovirus with p16 gene exerts antitumor effect on laryngeal carcinoma Hep2 cells. ( 27277704 )
2016
44
Real-time in vivo diagnosis of laryngeal carcinoma with rapid fiber-optic Raman spectroscopy. ( 27699131 )
2016
45
Fisetin inhibits laryngeal carcinoma through regulation of AKT/NF-I_B/mTOR and ERK1/2 signaling pathways. ( 27551764 )
2016
46
Effect of airway dynamics on the development of larynx cancer. ( 26372301 )
2016
47
Thymoma with an incidental benign laryngeal mass mimicking laryngeal carcinoma: Case report. ( 26930331 )
2016
48
p53 codon 72 polymorphism and its overexpression in patients with laryngeal carcinoma: Prognostic implications. ( 27304453 )
2016
49
The clinical diagnostic value of target biopsy using narrow-band imaging endoscopy and accurate laryngeal carcinoma pathologic specimen acquisition. ( 27037849 )
2016
50
Expression and significances of MiRNA Let-7 and HMGA2 in laryngeal carcinoma. ( 27874955 )
2016
Sources

Variations for Larynx Cancer

About this section

Cosmic variations for Larynx Cancer:

9
(show top 50) (show all 659)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)		 Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM6927812 ZFHX3 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.4946C>T p.S1649F 16:72797736-72797736 14
2 COSM45571 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.593A>G p.E198G 17:7674938-7674938 14
3 COSM10662 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.743G>A p.R248Q 17:7674220-7674220 14
4 COSM10995 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.580C>T p.L194F 17:7674951-7674951 14
5 COSM11066 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.578A>T p.H193L 17:7674953-7674953 14
6 COSM10714 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.473G>T p.R158L 17:7675139-7675139 14
7 COSM10988 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.772G>A p.E258K 17:7674191-7674191 14
8 COSM11245 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.430C>T p.Q144* 17:7675182-7675182 14
9 COSM43690 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.592G>A p.E198K 17:7674939-7674939 14
10 COSM10905 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.451C>T p.P151S 17:7675161-7675161 14
11 COSM10779 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.818G>T p.R273L 17:7673802-7673802 14
12 COSM10888 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.378C>A p.Y126* 17:7675234-7675234 14
13 COSM6549 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.743G>T p.R248L 17:7674220-7674220 14
14 COSM12559 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.673-2A>T p.? 17:7674292-7674292 14
15 COSM43846 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.487T>C p.Y163H 17:7675125-7675125 14
16 COSM10893 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.824G>A p.C275Y 17:7673796-7673796 14
17 COSM10659 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.817C>T p.R273C 17:7673803-7673803 14
18 COSM44475 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.871A>T p.K291* 17:7673749-7673749 14
19 COSM10813 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.394A>G p.K132E 17:7675218-7675218 14
20 COSM11462 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.388C>G p.L130V 17:7675224-7675224 14
21 COSM44219 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.405C>G p.C135W 17:7675207-7675207 14
22 COSM6906 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.672+1G>A p.? 17:7674858-7674858 14
23 COSM44067 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.721T>A p.S241T 17:7674242-7674242 14
24 COSM11658 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.955A>T p.K319* 17:7673573-7673573 14
25 COSM44071 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.955A>G p.K319E 17:7673573-7673573 14
26 COSM11305 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.809T>C p.F270S 17:7673811-7673811 14
27 COSM44352 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.850A>C p.T284P 17:7673770-7673770 14
28 COSM43583 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.425C>T p.P142L 17:7675187-7675187 14
29 COSM10889 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.536A>G p.H179R 17:7675076-7675076 14
30 COSM10758 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.659A>G p.Y220C 17:7674872-7674872 14
31 COSM10660 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.818G>A p.R273H 17:7673802-7673802 14
32 COSM10777 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.715A>G p.N239D 17:7674248-7674248 14
33 COSM10742 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.578A>G p.H193R 17:7674953-7674953 14
34 COSM44456 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.668C>A p.P223H 17:7674863-7674863 14
35 COSM11166 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.406C>T p.Q136* 17:7675206-7675206 14
36 COSM10810 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.725G>T p.C242F 17:7674238-7674238 14
37 COSM43949 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.401T>G p.F134C 17:7675211-7675211 14
38 COSM43935 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.577C>A p.H193N 17:7674954-7674954 14
39 COSM10645 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.527G>T p.C176F 17:7675085-7675085 14
40 COSM44103 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.737T>A p.M246K 17:7674226-7674226 14
41 COSM10654 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.637C>T p.R213* 17:7674894-7674894 14
42 COSM44143 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.919+1G>A p.? 17:7673700-7673700 14
43 COSM10648 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.524G>A p.R175H 17:7675088-7675088 14
44 COSM44278 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.791T>C p.L264P 17:7673829-7673829 14
45 COSM43826 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.706T>A p.Y236N 17:7674257-7674257 14
46 COSM98254 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.782+1G>A p.? 17:7674180-7674180 14
47 COSM11374 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.752T>A p.I251N 17:7674211-7674211 14
48 COSM44678 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.415A>T p.K139* 17:7675197-7675197 14
49 COSM43947 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.614A>G p.Y205C 17:7674917-7674917 14
50 COSM45544 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.947C>T p.P316L 17:7673581-7673581 14
Sources

Expression for Larynx Cancer

About this section
Search GEO for disease gene expression data for Larynx Cancer.
Sources

Pathways for Larynx Cancer

About this section

Pathways related to Larynx Cancer according to GeneCards Suite gene sharing:

(show all 29)
# Super pathways Score Top Affiliating Genes
1
Endometrial cancer 37
Show member pathways
 12.77 CCND1 CDKN2A EGFR GSTP1 HSP90AB1 TP53
2
Drug metabolism - cytochrome P450 37
Show member pathways
 12.68 GSTM1 GSTM3 GSTP1 GSTT1 NAT2 NME1
3
Glioma 37
Show member pathways
 12.62 CCND1 CDKN2A EGFR FHIT MMP2 TP53
4
Gastric cancer 37
Show member pathways
 12.58 CCND1 CDKN2A EGFR GSTM1 GSTM3 GSTP1
5
MicroRNAs in cancer 37
12.39 CCND1 CD44 CDKN2A EGFR MIR21 TP53
6
HTLV-I infection 37
12.34 CCND1 CDKN2A TERT TP53
7
Glutathione metabolism 37 22 1
Show member pathways
 12.21 GSTM1 GSTM3 GSTP1 GSTT1
8
Proteoglycans in cancer 37
12.18 CCND1 CD44 EGFR MIR21 MMP2 TP53
9
Colorectal Cancer Metastasis 64
12.09 CCND1 EGFR MMP2 TP53
10
Pathways in cancer 37
12.08 CCND1 CDKN2A EGFR GSTM1 GSTM3 GSTP1
11
AKT Signaling Pathway 67
12.07 CCND1 EGFR HSP90AB1 TP53
12
NRF2 pathway 1
12.02 GSTM1 GSTM3 GSTP1 HSP90AB1
13
Direct p53 effectors 1
11.96 CTSD EGFR MMP2 TP53
14
Glioblastoma Multiforme 64
11.87 CCND1 CDKN2A EGFR TP53
15
Small cell lung cancer 37
11.78 CCND1 FHIT TP53
16
Validated targets of C-MYC transcriptional activation 1
11.71 NME1 TERT TP53
17
Acetaminophen Pathway (therapeutic doses), Pharmacokinetics 61
Show member pathways
 11.7 GSTM1 GSTP1 GSTT1
18
Regulation of Wnt-mediated beta catenin signaling and target gene transcription 1
11.69 CCND1 MMP2 TERT
19
Fluid shear stress and atherosclerosis 37
11.64 GSTM1 GSTM3 GSTP1 GSTT1 HSP90AB1 MMP2
20
Bladder cancer 37 1
11.63 CCND1 CDKN2A EGFR MMP2 TP53
21
Regulation of Telomerase 1
11.6 CCND1 EGFR TERT
22
Cell adhesion_ECM remodeling 22
11.55 CD44 EGFR MMP2
23
Platinum drug resistance 37
11.5 CDKN2A GSTM1 GSTM3 GSTP1 GSTT1 TP53
24
Hepatitis C and Hepatocellular Carcinoma 1
11.47 CCND1 CD44 TP53
25
Photodynamic therapy-induced AP-1 survival signaling. 1
11.43 CCND1 CDKN2A EGFR MMP2 TP53
26
Busulfan Pathway, Pharmacodynamics 61
Show member pathways
 11.39 GSTM1 GSTP1 NAT2
27
Platinum Pathway, Pharmacokinetics/Pharmacodynamics 61
11.13 GSTM1 GSTP1 GSTT1
28
Naphthalene metabolism 22
11.01 GSTM1 GSTP1 GSTT1
29
Etoposide Pathway, Pharmacokinetics/Pharmacodynamics 61
10.82 GSTP1 GSTT1
Sources

GO Terms for Larynx Cancer

About this section

Cellular components related to Larynx Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytosol GO:0005829 9.77 CCND1 CD44 CDKN2A FHIT GSTM1 GSTM3
2 mitochondrion GO:0005739 9.76 CDKN2A FHIT GSTP1 HSP90AB1 MMP2 NME1
3 cytoplasm GO:0005737 9.5 CCND1 CDKN2A EGFR FHIT GSTM1 GSTM3

Biological processes related to Larynx Cancer according to GeneCards Suite gene sharing:

(show all 19)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of gene expression GO:0010629 9.84 ENG MIR21 NME1 TERT
2 positive regulation of protein phosphorylation GO:0001934 9.81 CCND1 EGFR ENG MIR21
3 negative regulation of apoptotic process GO:0043066 9.8 CD44 EGFR GSTP1 HSP90AB1 MIR21 TERT
4 positive regulation of protein kinase B signaling GO:0051897 9.78 EGFR ENG HSP90AB1 MIR21
5 response to estradiol GO:0032355 9.75 CCND1 EGFR GSTP1
6 xenobiotic metabolic process GO:0006805 9.74 GSTP1 HSP90AB1 NAT2
7 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.73 CD44 EGFR HSP90AB1
8 cellular response to drug GO:0035690 9.62 EGFR HSP90AB1 NME1 TP53
9 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.61 MIR21 MMP2 TERT
10 positive regulation of superoxide anion generation GO:0032930 9.58 EGFR GSTP1
11 mitotic G1 DNA damage checkpoint GO:0031571 9.55 CCND1 TP53
12 xenobiotic catabolic process GO:0042178 9.52 GSTM1 GSTM3
13 positive regulation of vascular smooth muscle cell differentiation GO:1905065 9.49 ENG MIR21
14 nitrobenzene metabolic process GO:0018916 9.46 GSTM1 GSTM3
15 cellular detoxification of nitrogen compound GO:0070458 9.4 GSTM1 GSTM3
16 response to UV-A GO:0070141 9.37 CCND1 EGFR
17 replicative senescence GO:0090399 9.33 CDKN2A TERT TP53
18 glutathione metabolic process GO:0006749 9.26 GSTM1 GSTM3 GSTP1 GSTT1
19 glutathione derivative biosynthetic process GO:1901687 8.92 GSTM1 GSTM3 GSTP1 GSTT1

Molecular functions related to Larynx Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.86 EGFR ENG FHIT GSTM3 HSP90AB1 NME1
2 protein kinase binding GO:0019901 9.8 CCND1 CDKN2A EGFR GSTP1 HSP90AB1 TP53
3 enzyme binding GO:0019899 9.63 CCND1 EGFR GSTM1 GSTM3 NME1 TP53
4 disordered domain specific binding GO:0097718 9.54 CDKN2A HSP90AB1 TP53
5 nitric-oxide synthase regulator activity GO:0030235 9.4 EGFR HSP90AB1
6 glutathione binding GO:0043295 9.13 GSTM1 GSTM3 GSTP1
7 glutathione transferase activity GO:0004364 8.92 GSTM1 GSTM3 GSTP1 GSTT1
8 protein binding GO:0005515 10.36 CCND1 CD44 CDKN2A CTSD EGFR ENG
Sources

Sources for Larynx Cancer

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....